본문 바로가기
HOME> 논문 > 논문 검색상세

논문 상세정보

Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of v.19 no.1, 2017년, pp.132 - 138   SCIE
본 등재정보는 저널의 등재정보를 참고하여 보여주는 베타서비스로 정확한 논문의 등재여부는 등재기관에 확인하시기 바랍니다.

Rationale and design of AXAFA-AFNET 5: an investigator-initiated, randomized, open, blinded outcome assessment, multi-centre trial to comparing continuous apixaban to vitamin K antagonists in patients undergoing atrial fibrillation catheter ablation

Di Biase, Luigi (Albert Einstein College of Medicine, Montefiore Hospital, NY, USA ) ; Callans, David (Hospital of the University of Pennsylvania, Philadelphia, USA ) ; Georg Hæusler, Karl (Center for Stroke Research Berlin & Department of Neurology, Charité—Universitatsmedizin Berlin, Germany ) ; Hindricks, Gerhard (Abteilung fur Rhythmologie, Herzzentrum Leipzig GmbH, Leipzig, Germany ) ; Al-Khalidi, Hussein (Department of Biostatistics & Bioinformatics, Duke University School of Medicine, USA ) ; Mont, Lluis (Hospital Clinic Barcelona, Barcelona, Spain ) ; Cosedis Nielsen, Jens (Department of Clinical Medicine, Aarhus University Hospital, Denmark ) ; Piccini, Jonathan P. (Duke University, Division of Cardiology Duke University Medical Center, Durham NC, USA ) ; Schotten, Ulrich (University Maastricht, Department of Physiology, Maastricht, Netherlands ) ; Kirchhof, Paulus (Atrial Fibrillation NETwork association (AFNET), Munster, Germany ) ;
  • 초록  

    Aims Catheter ablation is the most efficacious rhythm control therapy in atrial fibrillation (AF) patients. There is growing evidence that catheter ablation procedures are best performed during continuous oral anticoagulation, but outcomes are variable depending on the anticoagulation strategy or agent chosen. Specifically, there is a need to evaluate the peri-procedural use of non-vitamin K antagonist oral anticoagulants (NOACs) in patients undergoing catheter ablation of AF. The AXAFA-AFNET 5 trial will test whether peri-procedural anticoagulation therapy using apixaban is a safe alternative to vitamin K antagonist (VKA) therapy for patients undergoing catheter ablation of AF. Methods and results AXAFA-AFNET 5 is a randomized, prospective multi-centre study conducted in Europe and the USA. A total of 650 patients scheduled for AF ablation will be randomized 1:1 to undergo AF ablation on continuous treatment with the NOAC apixaban or with a VKA. Patients can undergo AF ablation after at least 30 days of continuous effective anticoagulation or after exclusion of atrial thrombi by transoesophageal echocardiogram. The trial includes a post-ablation magnetic resonance imaging substudy that will quantify silent brain lesions that can occur in neurologically asymptomatic patients after AF ablation. Patients will be followed on continuous anticoagulation for 3 months after the ablation. The primary outcome parameter of AXAFA-AFNET 5 is a composite of all-cause death, stroke, and major bleeding events. Conclusion The results of AXAFA-AFNET 5 will provide evidence informing about the safety of apixaban in ablation patients and on its efficacy including effects on silent brain lesions. AXAFA – AFNET 5 is an investigator-initiated trial sponsored by AFNET. The trial is supported by the DZHK (German Centre for Cardiovascular Research) and by the BMBF (German Ministry of Education and Research) and by Bristol-Myers Squibb/Pfizer Alliance.


  • 주제어

    Atrial fibrillation .   Ablation .   Oral anticoagulation .   Apixaban .   Warfarin .   Un-interrupted .   Stroke .   Bleeding.  

 활용도 분석

  • 상세보기

    amChart 영역
  • 원문보기

    amChart 영역

원문보기

무료다운로드
  • 원문이 없습니다.
유료다운로드

유료 다운로드의 경우 해당 사이트의 정책에 따라 신규 회원가입, 로그인, 유료 구매 등이 필요할 수 있습니다. 해당 사이트에서 발생하는 귀하의 모든 정보활동은 NDSL의 서비스 정책과 무관합니다.

원문복사신청을 하시면, 일부 해외 인쇄학술지의 경우 외국학술지지원센터(FRIC)에서
무료 원문복사 서비스를 제공합니다.

NDSL에서는 해당 원문을 복사서비스하고 있습니다. 위의 원문복사신청 또는 장바구니 담기를 통하여 원문복사서비스 이용이 가능합니다.

이 논문과 함께 출판된 논문 + 더보기